Market Research Report Germany Influenza Vaccine Market Research,Spain In | Page 2

Seasonal influenza vaccines need a yearly update because of constant evolution of
influenza
viruses in Europe and other countries as well. The match between selected vaccine
virus and those found circulating determine the effectiveness of seasonal influenza
vaccine, which vary from year to year. There is a meeting held each year in
February, in order to find best match and increase the vaccine efficiency and
effectiveness.
According to the market research report "Europe Influenza Vaccine Market &
Forecast (23 Countries Market & Vaccinated Population Data) By (Pediatrics
& Adult) & Vaccine Brands Analysis", the immunity that is extended by
influenza vaccines is not as long lived as the immunity following natural influenza
infection. This is particularly so for those who belong to the risk group, hence
people have to be vaccinated yearly. There are three influenza immunization
strategies which is feasible but Europe is the country where it is firstly most
important and widely used.
Discreet analysis has been made on the part of competitors. There are three major
players which have a major share of the influenza vaccine market in terms of
revenue.The key influencers with their products in the influenza vaccine market
are Sanofi Pasteur, GlaxoSmithKline (GSK), Seqirus, AstraZeneca and Protein
Sciences Corporation. There are other emerging players as well as if Novavax,
Daiichi-Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd and
VaxInnate are making novel technology based influenza vaccine, which may tend
to affect the market share in the future.
In Europe, protecting the vulnerable is one of the main strategies of immunization
programs, which is to directly or indirectly protect individuals that are more
vulnerable. Direct protection involves immunizing people who are more likely to
develop austere disease if they are infected by influenza viruses. There is also an
indirect protection strategy of immunizing those with close contact with people in
risk groups. The importance of this is growingas that the ordinary influenza
vaccines are more effective in healthy adults than older people and those with
chronic conditions, including immunodeficiency and this is now accelerated.